prikaz prve stranice dokumenta Farmakogenetika statina
Access restricted to students and staff of home institution
master's thesis
Farmakogenetika statina
Zagreb: University of Zagreb, School of Medicine, 2014. urn:nbn:hr:105:541077
Radman, Ivana
University of Zagreb
School of Medicine
Department of Internal Medicine

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Radman, I. (2014). Farmakogenetika statina (Master's thesis). Zagreb: University of Zagreb, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:541077

Radman, Ivana. "Farmakogenetika statina." Master's thesis, University of Zagreb, School of Medicine, 2014. https://urn.nsk.hr/urn:nbn:hr:105:541077

Radman, Ivana. "Farmakogenetika statina." Master's thesis, University of Zagreb, School of Medicine, 2014. https://urn.nsk.hr/urn:nbn:hr:105:541077

Radman, I. (2014). 'Farmakogenetika statina', Master's thesis, University of Zagreb, School of Medicine, accessed 22 November 2024, https://urn.nsk.hr/urn:nbn:hr:105:541077

Radman I. Farmakogenetika statina [Master's thesis]. Zagreb: University of Zagreb, School of Medicine; 2014 [cited 2024 November 22] Available at: https://urn.nsk.hr/urn:nbn:hr:105:541077

I. Radman, "Farmakogenetika statina", Master's thesis, University of Zagreb, School of Medicine, Zagreb, 2014. Available at: https://urn.nsk.hr/urn:nbn:hr:105:541077

Metadata
TitleFarmakogenetika statina
Title (english)Pharmacogenetics of statins
AuthorIvana Radman
MentorIveta Šimić (mentor)
Committee memberNada Božina (predsjednik povjerenstva)
Committee memberJasenka Markeljević (član povjerenstva)
Committee memberIveta Šimić (član povjerenstva)
GranterUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Zagreb
Defense date and country2014-03-19, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract
Primjena statina u posljednja dva desetljeća značajno je smanjila pobol i smrtnost od kardiovaskularnih bolesti (KVB) koje u svojoj podlozi imaju aterosklerozu. Taj se učinak prvenstveno temelji na smanjenju serumskog kolesterola male molekularne mase (LDL-kolesterol) čija se razina efikasnije snižava većim dozama statina. U brojnim studijama dokazana je korist od statina u primarnoj i sekundarnoj prevencijii KVB, a smanjenje rizika kardiovaskularnih incidenata linearno ovisi u smanjenju serumskog LDL-kolesterola. Međutim, postoji velika interindividualna varijabilnost u odgovoru na terapiju statinima. Uz brojne poznate čimbenike kao što su dob, spol, funkcija jetre i bubrega, istodobna primjena drugih lijekova, novija istraživanja pružaju dokaze da su genetske varijacije dobrim dijelom odgovorne za razlike u terapijskoj učinkovitosti statina. Sve donedavno farmakogenetičke studije su se uglavnom bavile pojedinačnim genima u istraživanju ovih učinaka. Kako su studije s ciljnim genima mogle objasniti samo mali dio opaženih varijacija s inkonzistentnim rezultatima pristupilo se studijama cijelog genoma te je nastala nova znanost – farmakogenomika. Akumulacija spoznaja o povezanosti genoma s bolestima i interakciji genoma i lijekova vodi prema personaliziranoj medicini koja je usmjerena k pojedinoj osobi primjenom preventivnih i prediktivnih DNA biljega. Cilj ovog rada je dati pregled spoznaja o farmakogenetici statina, rezultate studija cijeloga genoma i perspektive razvoja farmakogenomike i individualizirane medicine.
Abstract (english)
Over the last two decades the incidence and mortality of cardiovascular diseases (CVD) have been significantly lowered by use of statins. Low density lipoprotein (LDL) cholesterol is the main goal of statin therapy which efficacy is dose dependent. The results of many studies have shown benefits of statins in primary and secondary prevention of CVD and linear relationship between risk reduction of cardiovascular events and serum cholesterol rate lowering have been observed. However, there is large interindividual variability in response to statin therapy. There are many factors involved in variations in lipid responses to statins such as age, gender, renal and hepatic function and interaction with other drugs. The results of recent studies have shown genetic variations as a key role player in variability of statin responses. Until recently, pharmacogenetic studies have used mainly candidate gene approaches to investigate these effects. Since candidate gene studies explain only a small part of the observed variation and results have often been inconsistent, genome-wide association (GWA) studies have been introduced giving birth to pharmacogenomics. Accumulation of knowledge on genom-disease and genomedrug interactions leads to personalized medicine focused to individual person by use of preventive and predictive DNA markers. The aims of this review are to present facts on phamacogenetics of statins, results of GWA studies and future perspectives on pharmacogenomics and its translation into individualized medicine.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:105:541077
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsAccess restricted to students and staff of home institution
Terms of useLicence In copyright icon
Created on2015-12-16 10:22:03